Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial

Journal of Digestive Diseases

Volumn 18, Issue 12, 2017, Pages 698-703

  Manzhalii, Elina ^a   Virchenko, Oleksandr ^b   Falalyeyeva, Tetyana ^b   Beregova, Tetyana ^b   Stremmel, Wolfgang ^c  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

clinical trials; fat restricted diet; inflammation; non alcoholic fatty liver disease; non alcoholic steatohepatitis; probiotics

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; PROBIOTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIFIDOBACTERIUM LONGUM; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; LACTOBACILLUS RHAMNOSUS; LIVER STIFFNESS; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION; TREATMENT PLANNING; BLOOD; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PILOT PROJECTS; PROBIOTICS; PROSPECTIVE STUDIES;

EID: 85040728383     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12561     Document Type: Article

References (18)

1. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 2014; 20: 12956–80.
2. Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol 2017; 11: 357–69.
3. Sanyal AJ. NASH: a global health problem. Hepatol Res 2011; 41: 670–4.
4. Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016; 10: 394–406.
5. Salameh H, Hanayneh MA, Masadeh M et al. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum. J Clin Transl Hepatol 2016; 4: 175–91.
6. Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2016; 25: 159–65.
7. Stremmel W, Schmidt KV, Schuhmann V et al. Blood trimethylamine-N-oxide originates from microbiota mediated breakdown of phosphatidylcholine and absorption from small intestine. PLoS One 2017; 12: e0170742.
8. Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010; 4: 628–33.
9. Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52: 472–9.
10. Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011; 4: 325–34.
11. Watanabe M, Horai Y, Houten SM et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011; 286: 26913–20.
12. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601–9.
13. Cesaro C, Tiso A, Del Prete A et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011; 43: 431–8.
14. Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009; 21: 969–72.
15. Yoon JH, Lee JM, Joo I et al. Hepatic fibrosis: prospective comparison of MR elastography and US shear-wave elastography for evaluation. Radiology 2014; 273: 772–82.
16. Ferraioli G, Parekh P, Levitov AB, Filice C. Shear wave elastography for evaluation of liver fibrosis. J Ultrasound Med 2014; 33: 197–203.
17. Schulze J, Sonnenborn U. Yeasts in the gut: from commensals to infectious agents. Dtsch Arztebl Int 2009; 106: 837–42.
18. Manzhalii E, Hornuss D, Stremmel W. Intestinal-borne dermatoses significantly improved by oral application of Escherichia coli Nissle 1917. World J Gastroenterol 2016; 22: 5415–21.